Sanofi Rips Fed. Circ. Rehearing Bid In Repatha IP Fight

By Andrew Karpan ( June 1, 2021, 5:23 PM EDT) -- Sanofi is defending a controversial Federal Circuit ruling that axed two Amgen patents covering the cholesterol medication Repatha, arguing that Amgen's claims that the full court should review the ruling because it created too strict of an enablement test for patents in the biologics industry show that its rival is "swinging for the fences."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!